The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of Taysha Gene Therapies Inc (NASDAQ: TSHA) closed at $2.45 in the last session, up 2.51% from day before closing price of $2.39. In other words, the price has increased by $2.51 from its previous closing price. On the day, 1.94 million shares were traded. TSHA stock price reached its highest trading level at $2.595 during the session, while it also had its lowest trading level at $2.39.
Ratios:
We take a closer look at TSHA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.06 and its Current Ratio is at 4.06. In the meantime, Its Debt-to-Equity ratio is 0.82 whereas as Long-Term Debt/Eq ratio is at 0.79.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on April 09, 2024, initiated with a Overweight rating and assigned the stock a target price of $9.
On February 01, 2023, Jefferies Downgraded its rating to Hold which previously was Buy and also lowered its target price recommendation from $14 to $1.50.
Morgan Stanley Downgraded its Overweight to Equal-Weight on January 27, 2023, whereas the target price for the stock was revised from $23 to $3.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 17 ’23 when Manning Paul B bought 100,000 shares for $1.63 per share. The transaction valued at 163,000 led to the insider holds 16,566,667 shares of the business.
Alam Kamran sold 33,000 shares of TSHA for $76,890 on Aug 24 ’23. The Chief Financial Officer now owns 258,042 shares after completing the transaction at $2.33 per share. On Aug 16 ’23, another insider, Manning Paul B, who serves as the 10% Owner of the company, bought 16,466,667 shares for $0.90 each. As a result, the insider paid 14,820,000 and bolstered with 16,466,667 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TSHA now has a Market Capitalization of 458194112 and an Enterprise Value of 376139776. For the stock, the TTM Price-to-Sale (P/S) ratio is 29.66 while its Price-to-Book (P/B) ratio in mrq is 6.11. Its current Enterprise Value per Revenue stands at 24.344 whereas that against EBITDA is -5.373.
Stock Price History:
The Beta on a monthly basis for TSHA is 0.34, which has changed by 2.3561645 over the last 52 weeks, in comparison to a change of 0.24191546 over the same period for the S&P500. Over the past 52 weeks, TSHA has reached a high of $3.89, while it has fallen to a 52-week low of $0.50. The 50-Day Moving Average of the stock is -6.23%, while the 200-Day Moving Average is calculated to be 17.03%.
Shares Statistics:
According to the various share statistics, TSHA traded on average about 2.78M shares per day over the past 3-months and 1474010 shares per day over the past 10 days. A total of 186.96M shares are outstanding, with a floating share count of 128.62M. Insiders hold about 31.23% of the company’s shares, while institutions hold 62.24% stake in the company. Shares short for TSHA as of 1713139200 were 16067454 with a Short Ratio of 5.79, compared to 1710460800 on 15811726. Therefore, it implies a Short% of Shares Outstanding of 16067454 and a Short% of Float of 11.700000000000001.
Earnings Estimates
The current market rating for Taysha Gene Therapies Inc (TSHA) reflects the collective analysis of 10.0 analysts closely monitoring its performance.On average, analysts expect EPS of -$0.11 for the current quarter, with a high estimate of -$0.07 and a low estimate of -$0.19, while EPS last year was -$0.28. The consensus estimate for the next quarter is -$0.11, with high estimates of -$0.08 and low estimates of -$0.2.
Analysts are recommending an EPS of between -$0.3 and -$0.57 for the fiscal current year, implying an average EPS of -$0.41. EPS for the following year is -$0.48, with 9.0 analysts recommending between -$0.35 and -$0.63.
